Clinical trials
Cardiomyopathy, Hypertrophic trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
48 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 2 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2017 | 1 |
| 2018 | 6 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Recruiting | 12 |
| Active, not recruiting | 7 |
| Unknown status | 5 |
| Terminated | 3 |
| Not yet recruiting | 2 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bristol-Myers Squibb | 6 |
| Imperial College London | 5 |
| Barts & The London NHS Trust | 4 |
| Cytokinetics | 3 |
| University Hospital Birmingham | 3 |
| University of Manchester | 3 |
| MyoKardia, Inc. | 2 |
| University College, London | 2 |
| University of Edinburgh | 2 |
| Alder Hey Children's NHS Foundation Trust | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cardiomyopathy, Hypertrophic | 48 |
| Cardiomyopathies | 7 |
| Cardiomyopathy, Dilated | 4 |
| Angina Pectoris | 2 |
| Coronary Artery Disease | 2 |
| Heart Failure | 2 |
| Hypertrophy | 2 |
| Myocarditis | 2 |
| Apical Hypertrophic Cardiomyopathy | 1 |
| Atrial Fibrillation | 1 |
Trials
Showing 1 to 25 of 48. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.